Erin Mershon, STAT

Erin Mershon

STAT

Washington, DC, United States

Contact Erin

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

Recent:
  • STAT
Past:
  • Scientific American
  • The Boston Globe
  • Roll Call
  • POLITICO

Recent articles by Erin:

Health and science are on the ballot this election. Here's what we're watching

Tuesday’s votes will chart the course for the future of health care access, affordability, and public health writ large. → Read More

It’s official: parts of the government, including FDA, shut down early Saturday

House Republican leadership suggested late Friday there would be no further votes on legislation to fund the government ahead of the midnight deadline. → Read More

Unpacking the bold — and the bluster — in Trump’s plan to bring down drug prices

STAT unpacks some of the policies that have been in the headlines, and how significant — or insignificant — they might be. → Read More

HHS opens door to possibility of importing some drugs to drive down prices

It is one of the boldest ideas the administration has yet proposed as it has laid out a series of ways to bring down the cost of prescription drugs. → Read More

FDA Chief Slams Drug Makers for Stalling Release of Biosimilars

Americans could have saved $4.5 billion last year if these products were more available, agency official says → Read More

Appeals court rejects hospital industry's challenge on 340B changes

The Trump administration proposed slashing higher reimbursement for the drugs by about 27 percent — a roughly $1.6 billion cut for the industry in 2019. → Read More

In subtle mixing of messages, the drug industry tries to press Congress to lift burden for more drug costs

Pharma's latest ad campaign warns of a looming "cliff" for Medicare beneficiaries. But the industry is campaigning on a separate issue as well. → Read More

Mass. gets a thumbs-down on negotiating Medicaid prices, but Oklahoma wins on ‘value’ rebates

Top health officials offered the first clear signals of just how far they will let state Medicaid agencies go when negotiating discounts. → Read More

Key lawmaker calls for more scrutiny of hospitals using drug discount program — but no broader changes

A key Senate Republican renewed his commitment to ramping up oversight of a controversial drug discount program in a hearing Tuesday. → Read More

Drug makers considering 'substantial' decreases in prices, Azar says

Azar's remarks come about two weeks after President Trump pledged that “some of the big drug companies” would be announcing “voluntary massive drops in prices.” → Read More

Drug pricing advocates take aim at Democrats for supporting pharma

Fifty congressional Democrats signed on to a letter advancing the pharmaceutical industry's talking points — and now a drug pricing advocacy group is calling them out. → Read More

'Right-to-try' intended to weaken FDA, key senator says in blunt remarks

Sen. Ron Johnson, the author of the federal "right-to-try" law signed by President Trump this week, says the measure "intends to diminish the FDA's power over people's lives, not increase it." → Read More

Trump signs right-to-try legislation, making controversial measure law of the land

Terminally ill patients across the United States have a new way to ask drug makers to let them try unapproved therapies — a pathway that some experts worry sets a dangerous precedent. → Read More

Congress passes ‘right-to-try’ measure, sending hard-fought bill to Trump’s desk

The legislation would allow patients with life-threatening conditions ask drug makers to share or sell treatments that haven't yet been granted FDA approval, with some caveats. → Read More

FDA calls out 39 drug companies for allegedly blocking access to generics

The new list is part of the Trump administration’s efforts to lower prescription drug prices. → Read More

Ryan touts CREATES Act 'compromise' to lower drug prices

Congressional leaders are working on a "compromise" of the so-called CREATES Act, a longtime priority for generic drug makers, Speaker Paul Ryan said Thursday. → Read More

Right-to-try bill headed for vote puts bigger burden on FDA to protect patients, Gottlieb says

If the bill passes, the FDA will have to work harder to protect patients than it would if a different version of the legislation were advancing, Commissioner Scott Gottlieb said. → Read More

Which drug makers' medicines are racking up bigger and bigger bills for Medicare and Medicaid?

The Trump administration is calling out the companies behind spending increases as part of an effort to tout its updates to the Centers for Medicare and Medicaid Services "drug pricing dashboard" and the data available there. → Read More

Trump administration's drug pricing plan sparse on details

The policy blueprint offers few specific details about how any of these ideas would be implemented, and barely commits the government to doing anything, often saying that the Department of Health and Human Services “may” take certain actions. → Read More

Trump denounces ‘middlemen,’ largely spares pharma in drug pricing speech

President Trump delivered a measured and speedy address — and unveiled a menu of potential policy changes — that hardly touch the industry he once denounced. → Read More